CD34+CD7+CD5+CD1a-human progenitor T-cells produced in vitro and methods of using
AssigneeSunnybrook Health Sciences Centre
InventorsJuan Carlos Zuniga-Pflucker, Geneve Awong, Ross La Motte-Mohs
Life of this patent
Estimating the term…
Abstract
Human progenitor T cells that are able to successfully engraft a murine thymus and differentiate into mature human T and NK cells are described The human progenitor T cells have the phenotype CD34+CD7+CD1a−CD5− or CD34+CD7+CD1a−CD5+ and are derived from human hematopoietic stem cells, embryonic stem cells and induced pluripotent stem cells b\ coculture with cells expressing a Notch receptor ligand (OP9-DL1 or OP9-DL4) Such cells are useful in a variety of applications including immune reconstitution, the treatment of immunodeficiencies and as carriers for genes used in gene therapy.
Claims9
A method of producing a CD34+CD7+CDS+CD1a−progenitor T cell (pro T cell) comprising
- (a) culturing a mammalian hematopoietic stem cell (HSC) with a stromal cell that express a Notch ligand in a medium comprising Flt-3L and IL-7;
- and
- (b) determining the presence of CD34+CD7+CD5+CD1a− pro-T cells in the culture.
Dependencies are inferred from the claim text.